IMR Press / EJGO / Volume 37 / Issue 4 / DOI: 10.12892/ejgo3000.2016

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas
Show Less
1 Department of Obstetrics and Gynecology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
Eur. J. Gynaecol. Oncol. 2016, 37(4), 488–492; https://doi.org/10.12892/ejgo3000.2016
Published: 10 August 2016
Abstract

Objective: To examine efficacy and safety of biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas. Material and Methods: The recommended doses were determined in the phase I study. In the phase II feasibility study, the primary end-point was safety, and the secondary end-point was response rate and progression-free survival (PFS). Results: The recommended doses of docetaxel and carboplatin were determined to be 45 mg/m2 and AUC 3.0, respectively, in phase I study. In phase II feasibility study, no treatment-related death was observed. Most non-hematotoxicity cases were mild or moderate. Grade 4 neutropenia was confirmed in 13 patients (31.0%), whereas all cases showed tolerability with 2.6 days delay of anticancer drugs administration in both groups. Response rate was 55.0% in the ovarian carcinoma group, and average PFS was 8.7 months. In the endometrial carcinoma group, response rate was 50.0% and average PFS was 32.0 months. Conclusion: The present results showed that biweekly administration of docetaxel and carboplatin for advanced and recurrent endometrial and ovarian carcinomas results in acceptable side effects, response rate, and PFS.
Keywords
Biweekly administration
Docetaxel
Carboplatin
Endometrial carcinoma
Ovarian carcinoma
Share
Back to top